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ABSTRACT 
 
Orally ingested nutrients and drugs are selectively absorbed from our small intestines into the 
bloodstream through various membrane-integrated transporters. The present study focuses 
mainly on a specific absorption route, namely the proton dependent oligopeptide transporters 
(POTs). These transporter systems belong to the major facilitator superfamily (MFS) and are 
secondary active transporters. The aim of this thesis was to study the structure and 
mechanism of POTs from prokaryotic organisms. The project was divided in two phases. 
During the first phase, a high-throughput method was developed for rapid screening of 
integral membrane proteins (IMP) to identify suitable targets, constructs, and production 
conditions for structural studies (paper I). During the second phase of the project, X-ray 
crystal structures of the prokaryotic peptide transporter (PepTSo2) from the organism 
Shewanella oneidensis in complex with four different substrates were determined (paper II-
III). The structures revealed the overall conformational state of the protein as well as the 
architecture of the substrate-binding site. The protein was captured in an inward open 
conformation where the substrate-binding site was accessible to the cytoplasm but not to the 
periplasm. The bound peptides adopted extended lateral conformations with their N-termini 
interacting with a conserved polar pocket while their C-termini were in close proximity to a 
positively charged pocket. The results presented in papers I-III provide novel structural and 
mechanistic insights into prokaryotic peptide transporters. Interestingly, the binding site 
residues are highly conserved in the human peptide transporter homolog, PepT1. Hence, 
these results not only increase our understanding regarding prokaryotic peptide transporters 
but also shed light on the human homologs. Furthermore, results presented in this work may 
assist in design of pharmacologically active compounds into substrates of the human peptide 
transporter, creating orally administrated drugs. 
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1 Introduction  
 
The work presented in this thesis focuses on structural and functional understanding of 
proteins involved in nutrition and drug uptake. The first chapter offers an overview of basic 
concepts and principles relevant for the studies performed. The second and third chapters 
describe crystallography and protein structure determination methods and the forth chapter 
focuses on channel and transporter proteins.  
 
1.1 The central dogma of molecular biology 
The central dogma is a well-established principle explaining the connection between DNA, 
RNA, and proteins. It was first stated by Francis Crick in 1956 1 at a time when little 
evidence supported these ideas, hence the name dogma. It comprises three major processes 
for the transfer of information between DNA, RNA, and protein. The first process is 
replication: parental DNA is replicated to form a copy DNA by a set of enzymes where the 
main actor is DNA-polymerase. The second process is transcription: DNA is transcribed into 
RNA by RNA-polymerase. The third process is translation: RNA is translated by the 
ribosome into a polypeptide chain of amino acids resulting in a protein (Figure 1).  
Besides these three general processes, two additional routes exist: RNA can be replicated by 
the enzyme RNA dependent RNA polymerase and DNA can be generated from RNA by the 
retrovirus enzyme reverse transcriptase. Nevertheless information can never be reversed from 
a protein back to nucleic acids 2.  
 
Figure 1. An illustration of the central dogma. Double stranded DNA is transcribed into a single stranded RNA 
which is then translated into a protein.   
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1.2 Proteins  
The word protein was first mentioned 1838 by the Swedish chemist, Jöns Jacob Berzelius, in 
one of his letters to the Dutch chemist, Gerardus Johannes Mulder 3. 
"Le nom protéine que je vous propose pour l'oxyde organique de la fibrine et de l'albumine, 
je voulais le dériver de proteios parce qu'il parait être la substance primitive ou principale de 
la nutrition animale”  
Today we know that proteins are essential biological molecules that constitute the largest 
fraction of a cell where they are responsible for a vast array of functions. The structure of a 
protein can be divided in four levels: primary, secondary, tertiary and quaternary structure 
(Figure 2). The primary structure describes the sequence of amino acids that are linked in a 
specific order through covalent bonds. The linear primary structure folds into secondary 
structure elements, typically α-helices, β-sheets and turns. α-helices are right-handed spiral 
shaped structures while β-sheets are planar strands, both structures are stabilized by multiple 
hydrogen bonds 4. The next structural level is the tertiary structure, this is usually the 
structure referred to when describing a protein. It is stabilized by multiple hydrogen bonds 
together with salt-bridges, disulfide bonds and hydrophobic interactions. The fourth structural 
level, the quaternary structure, describes a large assembly of several proteins interacting to 
form larger oligomer arrangements. There are two types of oligomeric structures: homo- and 
hetero oligomers 5. As the names indicate, homo-oligomers are protein complexes composed 
of identical units held together by non-covalent interactions. In contrast, hetero-oligomers are 
protein complexes composed of different units. For example, hemoglobin is composed of 
four identical subunits and is thus referred to as a homo-tetramer. Eukaryotic ATP-binding 
cassette transporters (ABC transporters) are heteromeric complexes composed of an ATPase 
subunit and a transmembrane subunit. The different subunits in an oligomeric assembly may 
possess either independent or cooperative activity. Oligomeric protein complexes are 
abundant in nature, they offer advantageous features enabling the protein to reach higher 
orders of complexity including efficient pathways for functional control.  
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Figure 2. An illustration of the four protein structure hierarchies. The primary structure describes the linear 
sequence of amino acids. The secondary structure elements are mainly formed by α-helices and β-sheets. The 
secondary structure elements are organized into a tertiary structure giving the native shape of a protein. The 
quaternary structure is a complex composed of several proteins that are arranged either as a homo-oligomer or a 
hetero-oligomer. Figure adapted from the National Human Genome Research Institute. 
 
1.2.1 Membrane proteins 
Membrane proteins are hydrophobic molecules that are embedded in the complex lipid 
environment of the cell membrane. A typical cell membrane holds a broad set of different 
membrane proteins, all specialized in a particular function. They enable the cell to carry out 
various actions including the import of metabolites and export of waste, transmission of 
chemical signals and storage of chemical energy. Some membrane proteins are spanning the 
cell membrane, whereas others are bound to the membrane surface. Based on these 
characteristics, they are usually classified in two large groups: peripheral membrane proteins 
and integral membrane proteins (IMPs) (Figure 3). 
IMPs are fully integrated into the cell membrane by spanning it once or several times. Their 
amino acid composition is mostly hydrophobic thus enabling interaction with the 
hydrophobic cell membrane (Figure 3). Many IMPs create sluices through the membrane for 
the transport of various substances, this ability is based on their amphipathic secondary 
structures where the amino acid side chains alternate between polar and nonpolar property. 
The nonpolar side chains interact with the membrane acyl chains while the polar side chains 
form the inside of the pore. In this way, polar substances can be transported though the 
otherwise hydrophobic membrane 6. 
Peripheral membrane proteins are loosely attached to the membrane and they do not 
interact with the hydrophobic core of the membrane as extensively as the IMPs (Figure 3). 
Instead, they attach in a reversible manner to the membrane. The reversible nature enables 
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them to shuttle between the membrane and the cytosol allowing them to be involved in tasks 
such as cell signalling 7.  
  
Figure 3. Schematic representation of different types of membrane proteins. 1-2 shows IMPs that span the cell 
membrane as alpha helices or beta-sheets respectively. 3-4 shows two ways for peripheral membrane proteins to 
interact with the cell membrane.  
 
1.3 The E. coli cell membrane 
Escherichia coli (E. coli) is the most studied prokaryotic model system from where much of 
our knowledge about genetics, biochemistry and biophysics is based. A typical E. coli cell is 
rod shaped with the dimensions of 2 - 4 µm in length and 1 - 2 µm in width 8. It is part of our 
normal gut flora and it can be found in the lower intestines of warm-blooded organisms. An 
E. coli cell is surrounded by a protective membrane made up by a lipid bilayer. Lipids are 
amphiphilic molecules consisting of a hydrophilic head group and two hydrophobic tails. In a 
polar solution, lipids self-organize into bilayers by exposing the hydrophilic head groups to 
the polar solutions while hiding their hydrophobic tails inside the bilayers. The lipid bilayers 
can be further divided into an inner and an outer leaflet (Figure 4). There are numerous types 
of lipids, all with different chemical properties of the head groups and the tail structures. In 
the following section, the different compartments of an E. coli cell membrane: the outer 
membrane (OM), the periplasm, and the inner membrane (IM) will be described (Figure 4). 
The two leaflets of the E. coli OM are asymmetrical with regards to their lipid constitution. 
The outer leaflet is composed mainly of lipopolysaccharides; they maintain the rigidity of the 
cell, contribute to the negative charge of the membrane and are responsible for the immune 
response initiation in mammals when exposed to pathogenic E. coli stains 8, 9. The inner 
leaflet of the OM, on the other hand, is composed of a mixture of three glycerol-
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phospholipids: the zwitterionic glycerol phosphatidyl ethanolamine (PE), the anionic 
phosphatidylglycerol (PG), and the anionic cardiolipin (CL) 9. IMPs located in the OM are 
predominantly composed of β-strands forming β -barrels. Porins are an example of OM β-
barrel proteins responsible for the passage of a wide range of molecules over the OM.  
The periplasm is a compartment sandwiched between the OM and the IM. It encloses a 
strong peptidoglycan mesh layer that gives the cell its shape and structure.  
The two leaflets of the IM consist mainly of glycerol-phospholipids 9. The IM harbours a 
range of membrane proteins mainly with an α-helical structure, proton dependent 
oligopeptide transporters are examples of α-helical IM proteins.   
It should be mentioned that lipids also possess non-membrane related functions. They are for 
example involved in biochemical signalling where they act as secondary messengers. One of 
the examples is the lipid triacylglycerol (DAG) which is involved in the activation of protein 
kinase C responsible for substrate phosphorylation 10.  
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic illustration of an E. coli bacterium. The cell is cut in half to visualize the content of the 
cytosol and cell membrane. The OM is exposed to the outside environment and contains β-barrel proteins 
responsible for the transport of molecules. The IM contains α-helical IMPs responsible for the transport of 
molecules from and to the cytosol. The periplasm is a rigid structure sandwiched between the OM and the IM.  
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1.4 Recombinant protein production in E. coli 
To pursue structural studies on IMPs, large quantities of pure and homogenous protein is 
required. However, the natural abundance of these proteins is often too low to accumulate. 
Therefore, recombinant production of IMPs in E. coli has proven to be a robust strategy. The 
E. coli cell is in fact used as a protein factory, offering in optimal cases an easy-to-handle 
way of producing adequate quantities of proteins at low cost. Another advantage is the 
possibility to screen for optimal protein production strategies by varying for example the E. 
coli strains and expression conditions. Nevertheless, there are some bottlenecks in the E. coli 
IMP production process. Some of the most common issues are low expression yields, other 
more serious issues are cell toxicity or formation of aggregated proteins called inclusion 
bodies. The reason for such effects is the enormous stress imposed on the E. coli transcription 
and translation systems during overexpression of a particular protein 11.  
 
1.4.1 BL21(DE3)/pET protein production system 
BL21(DE3) is an E. coli strain specially generated in 1986 by Studier et al. with the aim of 
improving protein production 12. Two main modifications are present in this strain. The first 
modification is the introduction of a lambda bacteriophage DNA segment (DE3) carrying the 
lacI gene, the lacUV5 promoter, the lacZ gene followed by the T7 RNA polymerase (RNAP) 
gene, all located at the E. coli chromosomal DNA. The second modification is the 
introduction of an extra-chromosomal circular DNA vector, pET-vector (plasmid for 
expression by T7 RNA polymerase), containing a T7 promoter region upstream of the 
multiple cloning site where the target protein gene is inserted (Figure 5). This expression 
system takes advantage of the high selectivity of T7 RNAP for the T7 promoter. The target 
protein gene can therefore only be transcribed by the T7 RNAP. Nevertheless, the 
transcription of T7 RNAP is governed by the lacUV5 promoter, a mutated version of the lac 
promoter. Under normal circumstances, a lac repressor is bound to the lac operon, thus 
inhibiting the E. coli RNAP from transcribing T7 RNAP. Only when the lactose mimic 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) is added to the cells, the repressor is released 
and T7 RNAP is transcribed. Subsequently, the T7 RNAP transcribes the target protein gene 
located in the pET vector.  
The BL21(DE3) strain was further improved by knocking out two proteases, the outer 
membrane protease OmpT and the cytoplasmic protease Lon 13,14. Both these proteases were 
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known for having a negative effect on the target protein during expression and purification. 
Taken together, the combination of the pET vector, the lacUV5 promoter and the knock-out 
of OmpT and Lon make the E. coli strain BL21(DE3) a highly powerful and appreciated tool 
for heterologous protein production.  
 
 
Figure 5. An illustration of the BL21(DE3) expression system. Under normal circumstances a lac repressor is 
bound to the lac operon inhibiting production of T7 RNAP. Addition of IPTG (1) results in the dissociation of 
the lac repressor (2) enabling the production of T7 RNAP (3). The produced T7 RNAP recognizes its T7 
promoter on the pET vector and is thus responsible for the transcription of the target gene (4). The resulting 
target mRNA is then translated by the ribosome.   
 
1.4.2 Detergents 
Detergents are typically used for the isolation and solubilization of IMPs from the cell 
membrane since they offer a lipid mimetic environment for hydrophobic proteins. The 
general structure of detergents is similar to lipids - a polar head group fused to a nonpolar 
hydrophobic acyl chain tail. However there are two major differences between them: first, 
detergents consist of only one acyl chain tail structure while lipids consist of two, second, 
detergents used for IMP solubilization are cone shaped enabling them to form micelle 
structures while bilayer-forming lipids have a cylindrical overall shape (Figure 6 A-B) 15. 
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When exposed to aqueous solution, detergent micelles form spontaneously only if the 
detergent concentration is above the critical micelle concentration (CMC). Exposing the cell 
membrane to detergents at a concentration above their CMC will result in protein:detergent 
complexes where the detergent tail structures interact with the hydrophobic parts of the 
proteins while the hydrophilic detergent head group keeps the complex soluble (Figure 6 C).   
Detergents are often classified into three groups based on the nature of their polar head 
groups: nonionic, zwitterionic or ionic. Nonionic detergents consist of a hydrophilic head 
group such as maltose and are generally mild on IMPs as they do not disrupt any structural 
features, N-Dodecyl-β-D-maltopyranoside (DDM) is a widely used nonionic detergent. 
Zwitterionic detergents possess a net zero charge just like nonionic detergents, yet they are 
less mild as they might disrupt protein interactions. A typical zwitterionic detergent is 
lauryldimethylamine oxide (LDAO). Ionic detergents are efficient in solubilizing membrane 
proteins but they are also the least mild type of detergents since they usually disrupt protein 
interactions. Sodium dodecyl sulfate (SDS) is an anionic detergent used for protein 
denaturation.  
 
 
 
 
 
 
 
 
 
Figure 6. Detergents and lipids. A) The overall cone shape of detergents enables them to form micelles. B) The 
overall cylindrical shape of lipids enabling them to form bilayers. C) Illustration of IMP solubilization: the 
detergent destabilizes the lipid bilayer and extracts the protein from the membrane. The final protein-detergent 
complex might also contain lipids. Figure adapted from 16  
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1.4.3 Purification of Integral membrane proteins 
The aim of protein purification is to isolate a specific target protein from a complex mixture 
by successive purification until a state of homogeneity is reached. Common purification 
strategies include steps such as centrifugation, affinity chromatography and size-exclusion 
chromatography where protein characteristics such as size, chemical features and affinity tags 
are exploited for separation.  
The first step in a typical IMP purification procedure is the cell lysis where cells are broken 
by chemical or mechanical means, repeated freeze-thawing cycles, sonication or 
homogenization. Lysed cells are then subjected to low speed centrifugation for the isolation 
of cell debris followed by high-speed centrifugation, for the isolation of the cell membrane 
fraction 17.  
Subsequently, IMPs need to be extracted from the membrane fraction. This is usually 
accomplished by solubilizing the membrane fraction in detergents providing a membrane-
mimetic environment for IMPs. Finding a suitable detergent for a specific IMP is an intricate 
process, there are no general rules to follow hence the choice of detergent has to be optimized 
experimentally for each target protein. Choosing a suboptimal detergent might result in 
inefficient or heterogeneous solubilization, loss of protein function and stability or in the 
worst case, protein precipitation. Therefore, detergent screening is usually performed such as 
described in Paper I 18.
 
Detergent solubilized IMPs are commonly purified by affinity chromatography, a widely 
used technique based on the interaction between two molecules such as antigen and antibody. 
Immobilizing one interaction partner in the stationary phase of a column enables the binding 
and enrichment of the other interaction partner. Immobilized metal ion affinity 
chromatography (IMAC) is based on the interaction between histidine residues and divalent 
ions such as nickel. For this technique to work it is required that the target protein is fused to 
a poly histidine tag (His-tag) while the column stationary phase contains nickel. When 
running an IMAC experiment, His-tagged protein will be retained by the nickel on the 
column while other proteins will be washed away. The His-tagged protein is then released 
from the column by various methods such as, pH change or addition of a competitive 
molecule such as imidazole (Figure 7 A) 19, 20.
 
As a final purification step, size exclusion chromatography (SEC) is applied after IMAC 
purification. Here, proteins are separated on a column containing an inert porous matrix of 
spherical particles that allow separation of proteins based to their size. Unlike IMAC, SEC is 
  10
a nonbinding chromatographic method where proteins are eluted isocratically, without the 
need of a special buffer for elution. Large molecules exit the column before smaller 
molecules because small molecules get trapped inside the pores of the matrix. Protein elution 
is typically monitored by UV absorption at 280 nm while salt elution is monitored by its 
conductivity 21. A SEC run is displayed as a chromatogram where a monodisperse elution 
profile is indicative for a homogeneous protein sample (Figure 7 B). 
  
 
 
Figure 7. The purification principles of IMAC and SEC. A) The His-tagged recombinant protein
 
binds 
specifically to the nickel agarose stationary phase while untagged proteins are washed away. B) The matrix of a 
SEC column separates protein according to their size. The chromatogram shows a shorter retention time for large 
proteins (red) compared to small proteins (purple). Figure adapted from 21. 
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1.5 Thermal shift assay 
Natively folded proteins denature if subjected to extreme conditions such as high or low pH, 
elevated temperature or high salt concentrations. Thermal shift assays are based on the 
concept of destabilization and unfolding of proteins when subjected to elevated temperatures 
22
. The protein stability is represented by the melting temperature (Tm), a specific temperature 
where 50% of the protein in a sample is unfolded. In general, Tm is altered when a ligand or 
substrate binds to the protein, normally resulting in an increased intrinsic thermal stability 23. 
These features were described already in the 1950s by Koshland, Linderstrom-Lang and 
Schellman 24, and are utilized when studying protein-ligand interactions. The general 
approach is to heat up protein samples with and without a potential ligand in a controlled 
manner while monitoring the folding state as a function of temperature (Figure 8). Usually, a 
temperature shift greater than 2 °C is considered as a significant shift for a binding event.    
There are various methods used for detecting the thermal stability of proteins. The 
Differential Static Light Scattering method is one of them 25. It is a commonly used method 
based on the assumption that once a protein unfolds it immediately aggregates. Thus, 
monitoring the aggregation process (Tagg) through light scattering is an indirect way of 
measuring protein unfolding 26. This type of analysis is ideal for IMPs since no additional 
labelling or couplings of fluorescent dyes is needed and there is no interference with the 
detergents.  
The unfolding process may also be monitored by more conventional methods such as Sodium 
Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) or analytical 
gelfiltration analysis. Here, the sample is heated up with and without a ligand in a PCR 
thermal cycler to various temperatures followed by centrifugation to remove aggregated 
material. The concentration of remaining protein is then analysed by quantifying it on SDS-
PAGE or by peak intensity from an analytical gel filtration run.  
Another method, developed by Raymond Stevens et al. 27, is based on monitoring the thermal 
stability of proteins by a thiol-specific fluorochrome (N-[4-(7-diethylamino-4-methyl-3-
coumarinyl) phenyl] maleimide) that binds to core thiol residues upon protein thermal 
unfolding. This method is highly sensitive and compatible with detergent imbedded IMPs, 
however the major drawback is the requirement of free thiol residues in the protein core.  
Thermal shift assays have a very broad application area where protein stability can be 
analysed in various conditions. Examples of screening experiments include: finding an 
optimal buffer or detergent conditions and screening for ligands, substrates and binding 
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partners. Furthermore, a stabilizing molecule may be used for crystallization trials where it 
can either promote better quality crystals or, as performed in Paper II-III, identify a potential 
ligand for co-crystallization studies. 
 
  
 
Figure 8. A typical thermal aggregation curve showing thermal stabilization effect upon ligand binding. 
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2 X-ray crystallography 
 
The German physicist Wilhelm Conrad Röntgen was the first to report on X-rays in a paper 
published 1895 28. He discussed the properties of X-rays such as their ability to penetrate 
matter, to propagate in straight lines and to interact with photo-paper. Shortly after this 
discovery, X-rays were used to study the atomic constitution and bond interactions in salt 
crystals and diamonds. Already during this time it was known that proteins could form 
crystals. However, the techniques available were not sophisticated enough to elucidate 
complex protein structures. The first protein structure to be determined was a 2 Å structure of 
myoglobin that took 23 years for John Kendrew and Max Perutz to fully solve 29,30. The first 
membrane protein structure to be determined was a subunit from the photosynthetic reaction 
centre, solved in 1985 by Deisenhofer and colleagues 31. These first crystallographers were 
true pioneers, the importance of structural information to understand the molecular 
mechanism of biological system is therefore reflected by the large number of Nobel prizes 
that have been awarded for crystallographic work. 
Apart from X-ray crystallography, there are diverse methods that can be applied for structural 
studies. Some of the most popular current methods are nuclear magnetic resonance (NMR) 
and single particle cryo-electron microscopy (Cryo-EM). NMR is used for the study of 
protein structure, dynamics, and kinetics, however, there are limitations regarding the size of 
the protein where smaller proteins are preferred 32.  Although order parameters (eg. B-factors) 
and extent of disordered/flexibility can be obtained from crystallographic structures, NMR 
can give additional valuable information on protein dynamics which is not directly obtained 
in crystal structures. Cryo-EM is a promising technique for challenging proteins including 
IMPs. Based on new computation approaches and detectors, IMP structures can, at least in 
special cases, be resolved at atomic resolution without the need to crystallize or solve the 
phases of target protein. However, protein size is also a significant limitation for Cryo-EM 
where larger proteins are preferred 33.   
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2.1 Why do we need crystals? 
Protein crystals are fundamental in the course of macromolecular X-ray crystallography, the 
reason being that diffraction from a single molecule is too weak to be detected. Crystals are 
therefore suitable because of their periodic network of repeating protein arrays leading to an 
amplification of the diffracted X-ray signal. The smallest repeating units of a crystal are 
called unit cells and they are arranged according to a space group symmetry describing the 
position of each protein in the crystal 34 (Figure 9). One of the most frequently obtained space 
groups for membrane proteins is the P212121, consisting of a two-fold symmetry combined 
with a screw axis.  
 
 
Figure 9. A) The asymmetric unit is the smallest part that when arranged by the space group symmetry (B) can 
produce the unit cell (C). The unit cell is the simplest repeating unit in a crystal (D).  
 
Proteins are large, dynamic and flexible molecules whose native state rarely is a crystalline 
state which makes their crystallization a challenging process. Furthermore, protein crystals 
also need to be of a certain size and quality for high resolution X-ray diffraction. Moreover, 
there is no identified method for the prediction of an appropriate crystallization condition for 
a given protein. Indeed growing well-diffracting crystals has proved to be one of the major 
bottlenecks in the process of structure determination. Often, empirical screening of many 
crystallization conditions is necessary, where buffers, salts and organic solvents are varied, 
before a suitable condition is found. The crystallization process is thus a systematic search for 
parameters promoting crystal formation and due to the large number of possible parameters 
the search is often labour intensive and can take several years to achieve.  
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2.1.1 Protein crystallization – Vapour diffusion 
Vapour diffusion is the most commonly used method for crystallizing a protein. An isolated 
drop of concentrated homogenous protein is mixed with a precipitant solution and kept either 
as a sitting or hanging drop next to a reservoir containing higher precipitant concentration. 
Initially, this system is not in equilibrium but will eventually move towards equilibrium by 
vapour diffusion from the protein drop to the reservoir solution. Consequently, the protein 
concentration will gradually increase as vapour is escaping from the protein drop. If the 
conditions are optimal, the protein will pass through the undersaturated zone and the 
metastable zone and end up in the nucleation zone (Figure 10). This is a zone where the 
attractive forces between proteins are maximized, an ideal environment for a protein nucleus 
to grow. As the nucleus grows, the free protein concentration in the drop will decrease and 
the system will move to the metastable zone, where a crystal can slowly grow to maturity 35.  
  
 
 
 
 
 
 
 
 
 
Figure 10. The phase diagram for a crystallization event. The diagram consists of four zones where a successful 
crystallization event follows the green line. A suboptimal crystallization condition might result in precipitation 
(red line). This simplified diagram is controlled by the precipitant and protein concentration.  
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2.1.2 Crystallization optimization strategies 
The hydrophobic nature and the low intrinsic stability of IMPs make them very difficult to 
crystallize. Some of the screening strategies, used for membrane protein crystallization, are 
discussed below.  
Solubilizing IMPs from the cell membrane with detergents result in a protein-detergent 
complex where the detergents form a belt-like structure around the hydrophobic parts of the 
protein (Figure 6 C). The detergent not only keeps the protein soluble but may also shield 
possible crystal contacts. As a rule of thumb: longer chain detergents (low CMC) are more 
efficient in the solubilization process but also result in a larger detergent belt around the 
protein, unfavourable for crystallization. On the other hand, the use of shorter chain 
detergents (high CMC) allows more crystal contacts but at the same time increases the risk of 
protein aggregation due to the risk of exposing hydrophobic segments. Hence, it is crucial to 
find an optimal detergent for the solubilization, stabilization, and crystallization of IMPs, this 
is usually performed by screening many types of detergents 36.  
A promising approach in facilitating a crystallization event of challenging proteins is the use 
of high specificity binding partners to form a complex with the target protein. The resulting 
complex is then used for crystallization trials where the binding partner can offer additional 
crystal contacts that could increase the likelihood of achieving a higher quality crystal, 
resulting in higher resolution diffraction. The binding partner can be a fragment antigen 
binding (Fab), a cameloid single-chain nanobody or lysozyme. In addition, binding partners 
can be used for stabilizing and capturing the target protein in a specific conformation for 
crystallization. Some binding partners, such as lysozyme, can even be used for the phasing 
thereby facilitating structure determination of novel targets 37–39. 
It is well established that mobile regions in proteins could prevent the formation of crystals. 
One way of eliminating these parts is by performing limited proteolysis. This is an easy 
applicable method where the target protein is incubated with proteases such as trypsin, 
chymotrypsin or endoproteinase, followed by an analysis through SDS-PAGE. The protease 
is only able to digest flexible and unfolded parts of the protein that are exposed, generating a 
protein core that is resistant to further proteolysis, and better suited for crystallization. 
Limited proteolysis can be combined with Mass Spectrometry (MS) to identify the core 
sequence, making the generation of a new recombinant protein construct possible 40 41. 
The use of commercially available additive screens is an easy and fast way of improving the 
crystallization quality. Additive screen libraries consist of small molecules such as salts, 
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amino acids, dissociating agents, linkers, polyamines, osmolytes and reducing agents. These 
compounds can improve protein crystals by affecting protein-protein and protein-solvent 
interactions 42. 
Another commonly used method to optimize crystal diffraction is crystal dehydration. During 
dehydration experiments the solvent content in the unit cell is decreased in an attempt to 
shrink the crystals and hence generate improved crystal packing that could lead to improved 
diffraction. Dehydration can be performed manually by increasing the reservoir precipitant 
concentration in a vapour diffusion experiment, pushing the equilibrium towards less solvent 
in the crystal. It can also be performed in an automated manner at a synchrotron site where an 
unfrozen crystal is mounted on the Humidity Control Device (HC1b) followed by a 
controlled decrease of relative humidity around the crystal while the diffraction properties are 
tested simultaneously 43. 
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3 From data collection to model building  
 
A tremendous development has taken place in the field of macromolecular crystallography 
since the first protein structure was solved in 1958. Much of this development concerns 
computing technology where stronger and faster computers have facilitated improved data 
collection and processing. The same applies to model building and refinement processes 
where integrated programs can perform an automated task from processing to model building 
in basically one click of a mouse. Furthermore, a great development has also occurred around 
X-rays technologies and most important at the synchrotron facilities. Datasets that used to 
take several days to collect can now be collected within some minutes using very intense and 
focused X-rays. These advancements together with improvements in recombinant protein 
technologies have resulted in an increased number of solved protein structures of targets 
traditionally considered being challenging, such as IMPs 44 45. 
 
3.1 Why do we need X-rays? 
Objects smaller than the wavelength of visible light are impossible to study under a light 
microscope using traditional scattering. In other words, wavelength of 400-700 nm cannot be 
directly used to produce an image in the dimension of 1.5 Å which is necessary for accurate 
determination of protein structures. Therefore, a light source with a wavelength comparable 
to the smallest features of the object of interest has to be used. In terms of proteins, X-rays are 
used since they have a wavelength that falls into the range of carbon bonds (1.5 Å). X-rays 
used in crystallography are highly intense and focused beams, normally produced at 
synchrotron facilities 34.  
 
3.2 X-ray sources- synchrotrons 
In the early years of X-ray crystallography radiation was generated from diverse sources e.g. 
sealed-tubes and rotating anode instruments. These X-ray sources were relatively limited in 
both power and precision. Furthermore, the first generation synchrotrons were mainly 
dedicated for the research field of particle physics, structural biologists could only benefit 
from the side effect production of X-rays 46. The second-generation synchrotrons were built 
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particularly for structural biologists, bending magnets were used to enhance the X-ray 
quality. However, not until the construction of the third generation synchrotrons could the era 
of high-throughput crystallography truly advance. Third generation synchrotrons contain a 
booster ring and a storage ring surrounded by strong magnets and insertion-devises (Figure 
11). The production of X-rays in the third generation synchrotrons starts by heating up a 
cathode until electrons are emitted and transmitted through the injection system into the 
booster ring. The electrons are then accelerated close to the speed of light before they are sent 
to the storage ring. Magnets inserted in the ring steer the electrons around and X-rays are 
emitted every time the electrons are forced to bend. Furthermore, insertion devices that force 
the electrons to wiggle result in even stronger X-ray emissions. The X-rays are directed from 
the storage ring to the experimental beam lines where they can be tuned and used for 
macromolecular crystallography 47, 48.  
The next generation synchrotrons could be X-ray free electron laser (XFEL) offering even 
more advanced applications. This method is based on intense and ultra short X-ray pulses in 
the range of femtoseconds 49. The advantage here is the use of micro-crystals, meaning that 
there is no need of growing large crystals. The micro-crystals are injected into the intense 
beam through a liquid jet where they are hit by the X-ray pulses. Although the intense X-ray 
beam evaporates the microcrystals, diffraction information is collected from the intact crystal 
just before it evaporates 50. This method is still in the development phase, however the 
application of XFEL has recently been shown to be very valuable for studies of proteins 
containing redox metals such as photosystem II 51. 
 
 
Figure 11. An overview of a synchrotron facility showing the location and the connection between the four 
major components: injection system, booster ring, storage ring and beam line. Image adapted from the Soleil 
synchrotron.  
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3.2.1 Radiation damage 
Synchrotron beam intensity is measured in brilliance, taking into account the number of 
photons that are produced per second per cross section of the beam. The higher brilliance, the 
more photons reach the crystal and thus the better diffraction. Nonetheless these highly 
intense X-rays are harmful ionizing radiation. When a protein crystal is exposed to X-rays the 
electrons in the protein can absorb the photons and gain enough energy to be ejected from the 
atom. The free electrons then react with atoms to generate free radicals that change the 
chemical property of the protein in the crystal which often results in poor diffraction due to 
radiation damage. There are different ways of reducing the radiation damage. One approach 
is to flash freeze the crystal in liquid nitrogen. In this way, the mobility of the free radicals is 
slowed down leading to a prolonged lifetime of the crystal in the beam. However, the flash-
freezing step can be harmful for IMP crystals since they contain large volumes of solvent. A 
good cryogenic protector is therefore necessary to protect the crystal from being damaged by 
ice formation. Moreover, choosing an appropriate data collection strategy is crucial. Here, 
factors such as beam intensity, beam size, exposure time and detector distance have to be 
adapted to the crystal size and sensitivity. New synchrotron features such as the helical scan 
52
, allows for data collection over the entire length of the crystal hence spreading the radiation 
dose by constantly exposing new parts of the crystal to X-rays. This option is especially 
important for crystals that are sensitive to radiation damage such as IMPs.  
 
  21
3.3 Bragg’s law 
When X-rays hit a crystal they diffract in all directions leading to destructive or constructive 
interference. A constructive interference results in distinct diffraction spots while a 
destructive interference cancels out hence resulting in no diffraction spots. In 1913 Sir 
William Lawrence Bragg introduced a way of interpreting diffraction by X-rays. He 
envisioned the crystal as a set of discrete parallel planes separated by a constant distance (d) 
where the X-ray beam of known wavelength (λ) hits the crystal planes at an angle of (θ) 53 
(Figure 12).  
 
 
 
 
 
 
 
Figure 12. Bragg’s law derived by trigonometry gives nλ = 2 d sinθ. The blue lines represent 
two X-ray beams being scattered by two red dots representing atoms. Constructive 
interference occurs only when the interplanar spacing (d) is equal to an integer multiple (n) of 
the wavelength.  
 
According to Bragg’s law, the distance (d) between the atom planes in a crystal must be equal 
to an integral (n) multiple of the wavelength for the phases of the two beams to be the same 
thus leading to constructive interference. The Bragg’s equation, nλ = 2 d sinθ, shows a 
relationship between the interplanar distances (d) and the angle θ. The smaller (d), the larger 
angle of diffraction θ. Therefore, well-packed crystals with tight interplanar distances display 
higher resolution diffraction 54. 
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3.4 Data collection 
At the synchrotron site, the flash frozen crystal is mounted on a goniometer usually by an 
automated sample changer. While on the goniometer the crystal is under a constant cryogenic 
stream of nitrogen gas keeping a constant temperature of around 100 K. Generally, the crystal 
is first screened by collecting diffraction images from different angles. The diffraction spots 
are then assigned computationally to determine the space group and quality of diffraction. If 
the crystal is of sufficient quality, a strategy for data collection is proposed based on those 
results. During data collection the crystal is rotating on the goniometer allowing X-rays to 
pass through the crystal in different orientations. A full dataset is collected based on the space 
group information; the higher the symmetry space group the smaller data collection range is 
needed for a complete data set. However, for anomalous diffraction measurements more data 
is collected of each crystal when high redundancy data is preferred 55. 
 
3.5 The phase problem 
X-ray diffraction data contain information about the orientation hkl and intensities Ihkl of each 
reflection. The electron density p(xyz) can be described by the following equation where the 
measured intensities Ihkl are proportional to the structure factor amplitudes, Fhkl: 
 = 1	
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This equation has to be solved in order to achieve an electron density map. However, there is 
a problem. The incident X-rays are electromagnetic waves having a known wavelength, 
amplitude and relative phase, but only the amplitudes can be measured from the diffracted X-
rays. Information about the relative phase () is lost and without the phases the electron 
density equation cannot be solved hence the protein structure cannot be solved. This is the 
main bottleneck in X-ray crystallography and is widely known as “the phase problem”. Yet, 
there are some methods by which the phase problem can be solved, they will be discussed 
below 56,57.  
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3.5.1 Molecular replacement 
Molecular Replacement (MR) is the method of choice for solving the phase problem; it is a 
straightforward computer-based application where no additional wet lab experiments are 
needed. However, it does instead require an already known structure (search model) of a 
homologous protein structurally similar to the unknown target protein structure. As a rule of 
thumb a sequence identity of at least 25% is recommended for a MR procedure. The lower 
the identity, the more difficult it is to perform a successful MR. Today, the majority of all 
structures in the Protein Data Bank (PDB) are phased through MR and as more protein 
structures are solved, this method will see an even greater application.  
In theory, a MR procedure enables phase information to be transferred from the search model 
to the unknown homologous structure for initial phase calculations. For this to work, the two 
structures have to be in a similar position in space. This is performed in a two-step procedure, 
a rotational search followed by a translational search where the aim is to position the search 
model within the unit cell of the unknown target (Figure 13). Once the search model is 
positioned in the new unit cell, phases can be calculated and combined with the experimental 
diffraction intensities to yield an electron density map 58. However, since most of the 
structural information is in the phases, there is a risk for model bias in the new structure. 
Careful analysis and evaluation has to be performed by a so-called omit-map where parts of 
the structure are omitted in order ensure that they re-appear as a difference density in the new 
electron density map. Also simulated annealing can be performed to eliminate model bias and 
to find the global energy minima for the new structure 59.  
 
 
 
 
 
Figure 13. Molecular replacement visualized. The main principle of molecular replacement is the rotation and 
translation of the search model of the known structure (blue) to align with the target model of unknown structure 
(yellow). In this way, phases from the search model are applied on the target molecule.  
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3.5.2 Multiple isomorphous replacement 
At the time when the first protein structure was solved, molecular replacement was not a 
choice. Instead, the phase problem was solved by isomorphous replacement. It was a 
technique commonly used for small organic molecules but Max Perutz realized that it could 
also be applicable for large macromolecules. In contrast to MR, multiple isomorphous 
replacement (MIR) requires additional wet lab experiments to be performed. The underlying 
idea behind this technique is to incorporate heavy atoms in the crystals. This can be done 
either by soaking the crystals or by co-crystallization where the heavy atoms bind to the 
protein by interacting with specific amino acid residues. An important requirement here is to 
have derivative crystals with heavy atoms as well as a native crystal without any heavy 
atoms, all crystals must be isomorphous since the addition of heavy atoms must not change 
the cell-dimensions or the crystal packing. Preferably, a minimum of two different derivative 
crystals is needed to solve the phases without any ambiguity. Data sets are collected from the 
native and derivative crystals and since heavy atoms contain more electrons than ordinary 
protein atoms they will result in a distinct diffraction of higher intensity. From the distinct 
diffraction it is possible to measure the amplitude, the position of heavy atoms in the unit cell 
and the phase angle of the wave interfering with the heavy atoms 56. The accuracy of the 
predicted phase is validated by different statistical means. The agreement between calculated 
and observed heavy atom contribution between derivative and native structures is described 
by the Cullis R factor. Furthermore, the level of phase contribution by each derivative is 
described by the phasing power and the precision of the estimated phases is described by the 
figure of merit 55,60.  
 
3.5.3 Anomalous dispersion 
Anomalous dispersion is an additional strategy for solving the phase problem where heavy 
atoms are used without the need for isomorphous crystals since all diffraction data can be 
collected from a single crystal. The anomalous scattering is achieved by choosing an X-ray 
wavelength that is close to the absorption edge of the heavy atom. The electrons of the heavy 
atom will thus absorb and become excited by the X-rays. The excited electrons enter a higher 
energy shell and when they return to the lower energy shell, radiation is emitted causing a 
retardation of the diffraction wave. In a Multiple anomalous dispersion (MAD) experiment 
three data sets are normally collected; one data set at the peak absorption edge of the heavy 
atom, a second data at the inflections point of absorption and a third dataset at a remote 
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wavelength. The phases are then calculated based on the differences between structure factors 
in the data sets 55, 57. Most heavy atoms used for isomorphous replacement also offer a source 
of anomalous signal. Combining the two techniques gives SIRAS, Single isomorphous 
replacement with anomalous scattering, which is an alternative approach to solving the phase 
problem.  
 
3.6 Refinement 
Once the phase problem is solved and an initial electron density map is calculated, model 
building starts. The first model is usually far from being completed and in order to improve 
the model quality several iterative cycles of manual model building and refinements are 
performed, until the data converge. The aim is to build a protein structure that fits into the 
calculated electron density map as accurately as possible. A successful refinement procedure 
yields improved phases, giving a better electron density map where a more accurate model 
can be built and prepared for a new round of refinement (Figure 14). There are several tools 
available for evaluation of model building quality. One example is by using the 
Ramachandran plot to examine torsion angles of all amino acids in the model, keeping them 
in allowed regions is an indicator of a good model.  
When building the protein model, many parameters need to be taken into consideration, for 
example, stereochemistry such as bond length and bond angles of amino acids as well as 
chemical bond characteristics. At a typical membrane protein resolution of 3 Å, the ratio 
between collected data and model parameters is not equal; model parameters outnumber the 
parameters of the collected data. For this reason, restrains and constraints are used in the 
refinement to improve this ratio. In a restrained refinement certain freedom is given to the 
geometrical parameters. Restrained refinement therefore results in an elevated number of 
observations. In contrast, constrained refinement includes strict and exact values for 
geometrical parameters from which they may not deviate. Constrained refinement therefore 
results in a decreased number of parameters.  
The quality of the refinement is measured by the R-factor (Rwork):  
Rwork = 
∑ | !|"##	%&'#&()*+,-
∑ "##	%&'#&()*+,-  
where Fo are the observed structure factors and Fc are the calculated structure factors. The 
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Rwork value is a measure on how well the calculated values agree with the observed values. As 
a rule of thumb, the Rwork should be about 10 times the resolution and is usually given in 
percentage 54. There is always a risk of over fitting a model into noise, resulting in a false 
impression of having built an accurate model. For this reason 5-10% of the data are not 
included in the refinement process, instead they are used for the calculation of an Rfree value, 
which is a validation value of the refinement. Throughout the refinement, if the model is 
correctly built, both R-values should decrease. However, if a model is built into noise, the 
Rfree value will not decrease further 60.  
 
 
Figure 14. An overview of data collection and model building. X-rays are shot on a protein crystal rotating on a 
goniometer. The collected data are processed (indexing and scaling) and phases determined before a model can 
be built. The model building procedure consists of several iterative cycles followed by refinement.  
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4 Solute transport across membranes 
 
Living cells require a constant flow of molecules across the cell membrane. Nutrients and 
building blocks are taken up while metabolic by-products and xenobiotics are released. 
Although some small molecules are able to diffuse freely through the cell membrane, larger 
and charged molecules are often dependent on special assistance. Therefore, a broad range of 
transporters and channels have emerged through evolution. These IMP systems enable 
specific substrates to pass through the membrane, either by facilitated diffusion or by active 
transport. In this section, channels and transporters will be introduced, followed by an 
additional focus on transporters.  
 
4.1 Channels 
In the early 1950s, two scientists, Alan Hodgkin and Andrew Huxley studied functional 
aspects of ion channels. They developed an electrophysiology method, called voltage clamp, 
which allowed them to detect and measure action potentials through the giant axon of veined 
squid (Loligo forbesii). Eventually, these discoveries earned them a Nobel Prize in 
Physiology or Medicine in 1963 62,63. Today, we know that channels are IMPs specialized in 
facilitating the downhill movement of substrates, an energetically favourable process (Figure 
15). The opening and closing of a channel is typically controlled (gated) by either ligands or 
by variations in the membrane potential. Consequently, channels are grouped and named 
according to how they are gated.  
Ligand-gated channels are typically composed of a ligand-binding site located at the 
extracellular part of the protein. Ligand binding triggers a conformational change that 
subsequently leads to the opening of the channel pore. For example, channels located at the 
neural postsynaptic sites, such as the α1β2γ2γ-aminobutyric acid type-A (GABAA) activated 
channel, belong to this group. A release of GABAA neurotransmitter activates the channel 
and a flow of chloride ions is initiated in order to inhibit an action potential from firing 64.  
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Voltage-gated ion channels hold an intracellular voltage-sensing domain allowing them to 
open and close upon changes in the membrane potential. This type of channel is essential for 
the excitation and propagation of the action potential in nerve cell signaling. For example, the 
voltage-gated sodium channel belongs to this group and is responsible for the rising phase of 
the action potential 65.  
 
4.2 Transporters 
In contrast to channels, transporters can often promote uphill transport of substrates. This 
type of transport is energetically unfavourable and therefore in need of an energy source, such 
as ATP or an electrochemical gradient. Transporters typically bind a single substrate followed 
by a series of conformational changes before the substrate can be transported; consequently 
this type of transport is slower in comparison to transport through channels. Based on the 
type of energy source consumed, transporters are grouped into two main groups: primary 
active transporters and secondary active transporters 66.  
 
4.2.1 Primary active transporters 
Primary active transport systems are often transmembrane ATPases, an example is the ABC-
transporter which is a primary active transporter belonging to a large protein family with 
representatives in all kingdoms of life. They utilize the energy from ATP hydrolysis to 
catalyse the uphill transport of various substrates. Furthermore, they share a characteristic 
structural architecture of two transmembrane domains (TMDs) and two cytoplasmic 
nucleotide-binding domains (NBDs) (Figure 15). The alpha-helical TMDs form the pore 
section and undergo conformational changes during substrate transport. The amino acid 
sequence of this domain is variable, hence enabling broad substrate specificity. The ATP 
hydrolysing NBDs, on the other hand, are highly conserved. ABC transporters can be further 
divided into two subtypes based on the direction of transport: importers and exporters. ABC 
importers are exclusively present in prokaryotes, and depend on a binding protein (BP) for 
substrate binding and delivery to the pore. ABC exporters, on the other hand, are BP-
independent extrusion systems that are found in both eukaryotes and prokaryotes 67,68.  
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4.2.2 Secondary active transporters 
Secondary active transporters utilize the stored electrochemical gradient over the cell 
membrane to couple energetically un-favoured transport. They are divided into three groups 
on the basis of how the energy coupling is accomplished: symporters, antiporters and 
uniporters (Figure 15) 69.  
Symporters co-transport a minimum of two compounds, in the same direction. Typically, 
ions such as H+ and Na+ move down their concentration gradient, allowing a substrate to 
move up its concentration gradient. The transporter name usually reflects the type of ion 
being used, as in proton- or sodium- dependent symporter. Proton dependent oligopeptide 
transporters (POTs) belong to this class of symporters were they use the proton gradient for 
the uphill transport of di- and tripeptides 69 70.  
Antiporters follow the same principle, however the transport of substrates is in the opposite 
direction. A well-characterized representative of this class is the Na+/H+ exchanger (NhaA). 
This transporter is responsible for the regulation of intracellular pH by exchanging one 
external Na+ for an internal H+ 71.  
Uniporters, also known as facilitators, were added to the class of secondary transporters due 
to structural and functional similarities. They do however differ from the previously 
described transporters regarding the lack of coupled transport. Uniporters facilitate the 
downhill transport of substrates thus no energy is needed. The human glucose transporter 
GLUT1 is a uniporter responsible for the vital diffusion of glucose to the brain and other 
inner organs 72.   
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Figure 15. Various ways of substrate transport across the cell membrane.  
 
4.3 Is it a Channel or a transporter? 
Sometimes the boundaries between channels and transporters are unclear, especially 
regarding fast turnover transporters and slow turnover channels. Nevertheless, there are some 
key differences that may be used as hallmarks for the separation of the two. First, channels 
interact weakly with their substrates, allowing an unhindered flow down a concentration 
gradient. Transporters, on the other hand, bind to one substrate at a time and undergo specific 
conformational changes to perform the uphill substrate transport while consuming energy. 
Second, transporters alternate between several conformational states during a full transport 
cycle while exposing the binding site only to one side of the membrane at a time. Using these 
definitions, some proteins were recently re-grouped. One example is the former chloride-
conducting ion channels (CLC) which nowadays is referred to as a H+/Cl- transporter 73,74  
 
  31
4.4 Major Facilitator Superfamily transporters 
The major facilitator superfamily (MFS) is the largest group of secondary active transporters, 
containing over 100 different families 75. They are found in all kingdoms of life where they 
are specialized in the transport of various substrates including sugars, peptides, ions, 
vitamins, and fatty acids. The first structure of a MFS transporter, the oxalate:formate 
antiporter (OxlT), was solved in 2001 at a resolution of 6.5 Å 76,77. Since then, additional 
structures have been solved, mainly from prokaryotic sources such as the glycerol-3-
phosphate:phosphate antiporter (GlpT) 78, the D-xylose:H+ symporter (XylE) 79, the fucose 
symporter (FucP) 80, the multidrug transporter EmrD 81, the peptide transporters (PepT) 82, 
and the lactose transporter (LacY) 83. In recent years, the number of MFS transporters from 
higher eukaryotes has steadily augmented as a result of new technologies in combination with 
innovative strategies. The structure of human GLUT1 was solved at a resolution of 3.2 Å 72 
and the structure of the fungal phosphate transporter at a resolution of 2.9 Å 84. Taken 
together, these structures have revealed a common architecture of MFS transporters 
consisting of 12 transmembrane helices organized in two 6-helix bundles enclosing the 
substrate-binding site in the middle. Furthermore, these structures have also contributed to a 
deeper understanding of the various conformational states in the transport cycle of MFS 
transporters 85. 
 
4.5 The alternate access mechanism – an overview 
A general theory describing the transport-cycle of secondary active transporters was 
postulated already 50 years ago by Oleg Jardetzky 86. This theoretical paper states that 
secondary active transporters facilitate cargo translocation by shifting conformations without 
opening a continuous pore across the membrane. The transporter must therefore isomerize 
between at least two distinct conformations, an inward open and an outward open state. This 
type of transport mechanism is nowadays widely recognized as the alternate access 
mechanism. So far, several distinct MFS structures originating from different organisms have 
been solved providing significant evidence for the alternate access mechanism. Apart from 
structural evidence, the alternate access mechanism has also been studied by biochemical and 
biophysical assays as well as by computational models 87 88 89 90 
The molecular foundation for the alternate access mechanism is based on structural repeats 
found in all MFS transporters. The N- and C-terminal domains are related to each other by a 
pseudo-twofold symmetry axis perpendicular to the membrane plane. This type of symmetry 
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relationship is frequently encountered among transporters, suggesting a functional importance 
that might have arisen due to gene duplication. The two sub-domains might be further 
divided into the smallest primordial repeating unit from which the gene duplication events 
may have started. Here, two main hypotheses exist. The MFS transporters might have 
evolved via a gene duplication of a primordial 6-helical domain that in turn evolved either 
through gene triplication of a two-helix bundles or a gene duplication of a three-helix bundle 
75
 
91
. 
The structural repeats are stabilized by hydrogen bonds, some of these hydrogen bonds are 
termed gates since they alternate between the state of being broken and re-formed during the 
transport cycle. There are two groups of gates: intracellular gates and extracellular gates, also 
referred to as ‘outward-facing’ and ‘inward-facing’ gates 92,93. Altogether, a symporter 
transport cycle might start in the outward open state, stabilized by the cytoplasmic gates. At 
this state the binding site is exposed to the extracellular environment and hence accessible for 
substrates and ions. Once the binding site is fully occupied, a conformational change leads to 
an occluded state. The occluded state is an important transition that prevents the transporter 
from forming a leaky channel when switching from an outward open to an inward open 
conformation. This is the only conformational state where both the intracellular and the 
extracellular gates are closed. A transformation to the inward open conformation enables 
substrate and ion release into the cytoplasm thus completing the transport process. Now, the 
empty transporter cycles back to the outward open state for a new round of transport (Figure 
16).  
 
 
 
 
 
 
Figure 16. A schematic model of the alternate access transport mechanism of symporters. (1) The transporter is 
protonated followed by substrate binding (2) leading to an occluded state (3). The transporter then undergoes a 
conformational change to the inward open state (4), the substrate is released (5) and the transporter is de-
protonated (6). The transporter then cycles back to the outward open state, through an additional occluded state, 
and a new cycle can begin (7-8). 
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4.6 Proton dependent oligopeptide transporters 
E. coli have three systems for peptide uptake: Dipeptide-permease Dpp, Oligopeptide-
permease Opp, and Tripeptide-permease Tpp. The names indicate the backbone length of the 
transported peptides, nonetheless they do show an overlapping selectivity. The Dpp and Opp 
systems are primary active transporters that are not conserved in humans while the Tpp 
system belongs to the secondary active transporter family which is conserved in humans 94. 
POTs belongs to the Tpp system and are specialized in the uptake of short-chain peptides, an 
important and energy- providing strategy for the cell to acquire amino acids for downstream 
cell growth pathways. Furthermore, POTs are conserved in all kingdoms of life, from bacteria 
to man.  
PepT1 and PepT2 are the two human peptide transporters homologous to the prokaryotic 
POTs. PepT1 is localized in the brush border membranes of the small intestinal epithelium 
tissue where it is responsible for nutrient uptake 95 (Figure 17 A). PepT2 is expressed in a 
variety of organs including the kidneys where it is responsible for the reabsorption of 
peptides hence influencing the in vivo half-life time of absorbed peptides 96. In 1970, two 
American researchers, John Quay and Laura Foster, showed for the first time that PepT1 and 
PepT2 are responsible for the transport of short peptides as well as antibiotics 97. Today we 
know that these peptide transporter systems recognize and transport a broad variety of di- and 
tri-peptides including various compounds that resemble small peptides such as β-lactam 
antibiotics 98. They are therefore relevant for understanding absorption of orally administrated 
drugs and for designing drugs with improved absorption and distribution properties. 
Nevertheless, although PepT1 and PepT2 have been meticulously studied regarding substrate 
specificity and transport kinetics, there is still no structural information available (Figure 17 
B). The lack of structural information is mainly due to the complex and hydrophobic nature 
of human IMPs leading to complications from protein expression to crystallization. To 
circumvent this hurdle, prokaryotic homologous transporters are studied since they offer a 
less complex system providing a good starting point for better understanding PepT1 and 
PepT2. 
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Figure 17. An illustration showing the location of PepT1 in the human body. A) Once ingesting a protein-rich 
meal, secreted enzymes in the stomach start to digest the protein until a mixture of amino acids and small 
peptides remain. These short peptides are then transported across the guts and delivered through PepT1 to 
various organs where they are needed. B) Overall topology model of PepT1/PepT2 showing 12 TM helices and a 
long segment between TM helix 9 and 10. Figure modified after 99.   
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4.6.1 The overall architecture of POTs 
To date, structures of five different prokaryotic POTs have been determined by X-ray 
crystallography (Table 1). Those include:  PepTSo 100 from Shewanella oneidensis, PepTSt 101,  
from Streptococcus thermophiles, GkPOT 104 from Geobacillus kaustophilus, YbgH from E. 
coli PepTSo2 82 from Shewanella oneidensis. These transporters consist of approximately 500-
600 amino acids sharing an overall low sequence identity (around 20%) but high structural 
similarity. They all exhibit the canonical MFS fold consisting of 12 transmembrane helices 
having both amino and carboxyl termini facing the cytosol (Figure 18). The helices are 
organized into two domains, the N-terminal domain (TM helix 1-6) and the C-terminal 
domain (TM helix 7-12), generating an overall shape of “∨/∧” where the highly conserved 
substrate-binding site is located in the centre. Furthermore, the two domains are linked 
together by two additional helices, named HA and HB, sharing low sequence conservation 
and are absent in PepT1 and PepT2. The function of HA and HB is currently unknown, 
however there are various speculations claiming a role in stability, oligomerization or 
regulation of transport 105.  
 
Table 1. Known peptide transporter structures. 
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Although POTs differ in overall sequence identity across organisms they still share three 
highly conserved signature motifs 106. Two of the motifs (ExFxxYGM and FYxxINxG) are 
specific for the PepT family members while the A-motif (GGxxxDxxxG) is specific for the 
MFS family. All three motifs are located within the first five helices and are predicted to have 
different functional roles 107. A recent paper published by Zhao et al. 103 propose that the POT 
specific motifs are involved in substrate recognition in the binding site, while the MFS 
specific motif functions as a conformational switch, stabilizing certain conformations in the 
transport cycle. Furthermore, a mutation in any of these signature motifs results in reduced or 
lost transport activity. 
 
Figure 18. Overall structure of PepTSo2 visualized from different orientations: side view, periplasmic view and 
cytoplasmic view.
 
The protein was crystallized in an inward open state where the binding site (yellow) is 
accessible from the cytoplasm. HA and HB helices are coloured grey.  
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4.6.2 The binding site 
The POT substrate-binding site is a cavity found in a central position between the N- and C-
domains. It is the most conserved part of the transporter, sharing an identity of about 90% 
between human and bacterial POTs. Studying substrate transport of prokaryotic POTs will 
therefore potentially provide valuable information also regarding the function and mechanism 
of PepT1 and PepT2. 
While studying the structure of PepTSo2 in paper II-III, we discovered a dipole-like charge 
distribution along the binding site by where the substrates were bound. The substrate N-
terminus interacted with the negatively charged part of the pocket consisting of E402, N151 
and N329, while the substrate C-terminus interacted with the positively charged part of the 
pocket consisting of R25 and K121 (Figure 19 A). One of the main mysteries of the binding 
site is the broad substrate specificity. How is it possible for a single site to recognize and 
transport substrates ranging from di- and tri-peptides to drugs? Some clues can be found 
when studying the structural architecture of the binding site. A striking feature is the large 
number of tyrosine residues in the binding site and in its vicinity. It is likely that tyrosines 
play an important and versatile role in the substrate coordination since they are able to 
interact with the substrate through various types of interactions such as hydrogen bonds, 
hydrophobic and electrostatic interactions. Furthermore, tyrosine residues are also able to 
switch rotamers hence adapting the size of the binding site to the size of the substrate. The 
plasticity of the binding site is further amplified by the strategic location of R25 and K121, 
enabling peptides of different sizes to interact through their C-terminus (Figure 19 B).  
In 2013 Keisuke Ito et al. 108 investigated the substrate specificity of Ptr2p, a POT from 
Saccharomyces cerevisiae, by using a dipeptide library. The results showed a remarkable 
substrate preference biased towards di-peptides consisting of essential and semi-essential 
amino acids. In 2014, we investigated the substrate specificity of PepTSo2 was investigated by 
a proteoliposome based uptake assay of tripeptides (Paper III). Results from this study 
showed a preference for small and medium sized hydrophobic residues but a disfavour for 
glycines 109. 
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Figure 19. A) A close up view of the PepTSo2 binding site where three structures with substrates are aligned 
(AAA, AY and AYA). Conserved side chains responsible for coordinating the substrates are illustrates as sticks 
and the dipole like charge distribution is illustrated as red and blue patches. B) Differences in the coordination of 
substrate C-termini by R25 and K121. 
 
4.6.3 Proton coupling 
As mentioned earlier, peptide transporters are secondary active symporters utilizing the 
electrochemical gradient stored over the cell membrane to energize for uphill substrate 
transport. A prerequisite for such a transport system is a tight membrane not permeable for 
unspecific ion leakage, enabling ion gradients to be maintained and used in a controlled 
manner to drive metabolic processes. Different types of ion gradients are present over the cell 
membrane such as Na+, Cl-, and H+. However, the most commonly used ion gradient by 
peptide transporters is the proton gradient (H+) generated by specific membrane embedded 
proton pumps such as the ATPase and the respiratory chain proteins. Since the proton 
gradient is composed of both a charge (∆Ψ) and pH (∆pH) it is usually referred to as the 
electrochemical force.  
It is generally accepted that for secondary active symporters, the protonation event occurs at 
titratable residues in the vicinity of the substrate-biding site. Nevertheless, the molecular 
details are still obscure. The most studied and best-understood MFS transporter, LacY, 
undergoes a protonation event prior to sugar binding. Furthermore, the substrate:proton ratio 
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was predicted to be 1:1 110 and the release of the sugar was preceded by a de-protonation 
event 111. Daohua Jiang et al. investigated the proton coupling mechanism of the putative 
drug efflux protein YajR 107. According to their hypothesis, the outward open transporter 
binds a substrate prior to a protonation event, in this way preventing protons from leaking 
through the transporter. Also, an inward open YajR releases the substrate prior to a 
deprotonation event, thus preventing the substrate from being transported back. In a recently 
reported study of the peptide transporter YbgH 105, it was concluded that protons bind in 
response to substrate binding. Furthermore, the protonation site was predicted to be a cluster 
of residues, located in the vicinity of the substrate-binding site, serving as a sensor for 
substrate binding. Similarly, in a study of the cation/melibiose symporter, MelB, an 
analogous conserved cluster was identified as the protonation site 112. A study published by 
Parker et al. 113 provide some hints on the proton:substrate stoichiometry of PepTSt. Here, the 
proton-coupling stoichiometry was studied mainly by a reconstituted proteoliposome system 
in combination with radioactively labelled substrates or a pH sensitive dye fluorophore. 
Based on these experiments it was proposed that POTs use different proton stoichiometry 
depending on what type of substrate is being transported, 3:1 for tri-peptides and 4-5:1 for di-
peptides 113. Taken together, these results point towards significant variations in proton 
coupling and substrate translocation among and within MFS transporters. The proton 
coupling by PepTSo2 is still not well understood. The protein has three highly conserved 
titratable residues in the binding site: Glu21, Glu24 and Glu409. From the substrate bound 
structures, in PepTSo2, we predicted that Glu 402 was involved in binding of the substrate N-
terminus, leaving Glu 21 and 24 as the candidates for proton coupling. Interestingly, 
mutagenesis studies on the corresponding residues in PepTSt showed a loss of function 
emphasizing the importance of these residues 114.  
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5 Summary of papers 
 
5.1 PAPER I 
High-throughput analytical gel filtration screening of integral membrane proteins for 
structural studies 
 
Paper I describes a rapid and cost-efficient screening procedure that enables fast identification 
of protein constructs, expression strains and purification conditions for structural studies of 
IMPs.  In this workflow, we screened the expression of prokaryotic IMPs in E. coli. 
However, the overall procedure is also applicable for other target proteins or protein 
complexes produced in other expression systems.  
The screening strategy was designed as a pipeline divided into the following steps: construct 
design, protein expression screening, protein purification via IMAC and SEC, and finally 
crystallization. Furthermore, checkpoints with different criteria had to be fulfilled before a 
target could enter the next step. Selection of successful targets was based on the following 
criteria: correct DNA sequencing, expression yields, detergent solubilization potential and 
homogeneity of purified protein, along with crystallization hits in broad screens (Figure 20). 
A total of 48 prokaryotic IMPs were selected based on structural and functional novelty and 
on the existence of human homologs. Target DNA was cloned into pET vectors using the 
ligation independent cloning (LIC) system creating two constructs of each target, carrying a 
C-terminal or an N-terminal His-tag. Out of 96 possible constructs 93 were found to have a 
correct DNA sequence and were thus sent forward to the protein expression-screening step.  
Two E. coli strains were used for the small scale expression tests, BL21(DE3) and C41(DE3). 
The C41(DE3) strain belongs to the Walker strains and is optimized for overexpression of  
membrane proteins 115. Crude membrane preparations were used for evaluating protein 
expression levels using Western blot analysis in comparison to a reference protein. A 
minimum threshold for the expression level was set and targets expressing above this 
threshold were subjected to small-scale purification.  
  41
The small-scale purification procedure included the use of IMAC followed by SEC. Since the 
detergent choice is important for IMP homogeneity and stability, we performed detergent 
screening including five different detergents commonly used for membrane protein 
solubilization (FC12, DDM, LDAO, Cymal-5). Each membrane fraction was thus solubilized 
in those detergents prior to purification. Target purity and homogeneity was then evaluated 
by SDS PAGE and SEC elution profiles. 
Based on the small-scale purification results, targets were selected for large-scale expression 
and purification. The large-scale expression and purification strategy was performed in the 
same manner as the small-scale screening. Targets that eluted as monodisperse peaks from 
the SEC were concentrated and used for crystallization trials.  
A summary of the results from the screening pipeline is shown in Figure 21. Interestingly, 
Western blot analysis revealed higher protein expression levels for N-terminally His-tagged 
targets expressed in BL21(DE3) compared to C-terminally His-tagged proteins expressed in 
C41(DE3) cells. However this trend was reversed in the small-scale purification step. Here, 
targets expressed in E. coli strain C41(DE3) with a C-terminal His-tag eluted more often with 
a monodisperse SEC peak indicating a homogenous sample compared to targets expressed in 
BL21(DE3) with a N-terminal His-tag. A possible reason for this observation might be that 
adding an N-terminal His-tag could interfere with protein recognition and insertion into the 
membrane. Furthermore, measuring protein expression levels with Western blot analysis only 
gives a hint on the expression level, it does not give any information about protein quality and 
stability. A lesson learned from this screening pipeline was the successful combination of a 
C-terminal His-tag construct expressed in the C41(DE3) strain and solubilized in DDM.    
In conclusion, the screening pipeline enabled us to rapidly screen 48 IMPs and to identify 
candidates for structural studies. Using identical conditions for the small scale and the large-
scale procedure greatly accelerated the progress from analytical to preparative results, while 
ensuring a high success rate for the transition. Furthermore, the easy setup and low-cost 
permit this method to be used in many labs, where various targets and expression systems can 
be applied. Using the described procedures we were able to identify successful constructs and 
expression strains for various IMPs. In addition, we also generated crystals and collected 
initial diffraction data for six transporters: PepTSo2, PepTSt, a MATE transporter, an arsenate 
transporter, a folate transporter, and a xylose transporter. This underlines the efficiency and 
potential value of this type of screening procedure, which is of great utility, since large scale 
expression, purification and crystallization of IMPs is both challenging and labour intensive. 
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Figure 20. A flow chart of the screening pipeline, describing the pathway from construct design to 
crystallization optimization. The checkpoints are shown as coloured boxes.    
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Overview of the success rates in the screening pipeline. The circle diagrams show a percentage of 
targets passing through each phase (green) relative to the number of targets entering the first phase. 
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5.2 PAPER II-III 
- Structural insights into substrate recognition in proton dependent oligopeptide 
transporters 
- Selectivity mechanism of a bacterial homolog of the human drug-peptide 
transporters PepT1 and PepT2 
 
Based on the workflow developed in paper I, we identified a proton dependent peptide 
transporter from Shewanella oneidensis (PepTSo2) as a promising target for structural and 
functional studies. We were very interested in the structural basis for the multi-specificity of 
peptide transporters. In paper II and III, we present the inward open crystal structure of 
PepTSo2 in complex with four different substrates: an antibacterial peptidomimetic 
(alafosfalin), a di-peptide (AY), and two tri-peptides (AAA and AYA). All structures 
revealed a consistent substrate coordination mode guided by the dipole-like charge 
distribution in the binding site. The substrate backbones extend laterally across the binding 
site enabling the substrate N-terminus to interact with a negatively charged area, while the 
substrate C-terminus interact with a positively charged area (Figure 19 A). This observation 
confirms the already observed importance of both the N- and C-termini for substrate 
recognition and coordination. Furthermore, we observed that side-chains of tyrosine residues 
of substrates AY and AYA were interacting with a hydrophobic pocket found in the centre of 
the binding site.   
We realized early on in the crystallization process that PepTSo2 generated high quality crystals 
only when co-crystallized with a substrate and divalent ions such as zinc. Following these 
findings initial PepTSo2 crystals were generated and after several rounds of optimization, a 
condition was found where reproducible PepTSo2 crystals grew and diffracted to 3 Å. The 
diffraction was anisotropic meaning that it reached to the highest resolution diffraction only 
in certain directions. This feature is very common among IMP crystals and is likely to be 
connected to their crystal-packing type. The dataset was processed in space group P212121 
using anisotropic scaling with ellipsoidal truncation. The asymmetric unit consisted of two 
molecules held together as an artificial dimer by a zinc ion (Figure 22 A). 
Based on our gathered structural knowledge of PepTSo2, we divided the binding site in three 
pockets assigned to the interaction sites of the different substrate side chains. We thus aimed 
to obtain further insights regarding the notable broad substrate specificity of POTs, by 
mapping out preferred substrates. Thermal shift assays in combination with proteoliposome 
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uptake assays were performed using a tri-peptide library. Results emerging from this study 
confirmed that small and medium sized hydrophobic side chains were generally preferred by 
PepTSo2. We also observed that glycine residues were strongly unfavourable.  
Interestingly, a POT structure (GkPOT) from the prokaryotic organism Geobacillus 
kaustophilus, also co-crystallized with alafosfalin, was published simultaneous to our 
structure 101. In contrast to our study, the GkPOT protein carried a point mutation (E310Q) in 
the binding site. The authors argued that this mutation was necessary in order to capture 
alafosfalin in the binding site by mimicking the protonated state. Comparing the alafosfalin 
coordination in PepTSo2 with the one of GkPOT reveals some intriguing differences. 
Although the general alignment is in agreement with the lateral dipole charge distribution, the 
substrate coordination is quite different. The alafosfalin molecule in GkPOT is located closer 
to the periplasmic side of the binding site compared to PepTSo2. Furthermore, the difference 
was more pronounced at the C-terminal phosphate head group than in the N-terminus (Figure 
22 B). The observed shift in coordination could simply be explain by different transport 
modes but could also be due to the point mutation introduced in GkPOT. 
An additional study of a POT transporter co-crystallized with substrates was performed by 
Lyons et al. 114. Here, PepTSt from the prokaryotic organism Streptococcus thermophiles was 
co-crystallized with the peptides AF and AAA. While the AF peptide was coordinated in a 
similar fashion to our di- and tri-peptides i.e. in accord with the dipole moment of the binding 
site, the AAA coordination eas dramatically different from the common binding mode. The 
AAA substrate was instead bound in a vertical position where the C-terminus extends 
towards the periplasm. Thus, although PepTSo2 and PepTSt share a highly conserved binding 
site, the coordination of AAA is strikingly different (Figure 22 C). The authors speculate that 
this new binding mode enables PepTSt to coordinate a broader range of substrates. Moreover, 
although the structural resolution of the PepTSt was 2.5 Å, the substrate electron density was 
weak. Hence, the relevance of the proposed AAA binding mode needs further examination. 
An exciting feature revealed in Paper II was the tetrameric state of PepTSo2. While purifying 
PepTSo2 and other POT homologs by SEC we noticed an earlier retention time of PepTSo2, 
indicating a larger protein assembly. This was further analysed via Blue Native PAGE, cross-
linking with glutaraldehyde and negative stain electron microscopy. Results from these 
methods confirmed a tetrameric organization of PepTSo2 while the other characterized POTs, 
PepTSo, YjdL and YdgR were monomeric, except for PepTSt that might be a dimer. Further 
evidence for a homo-tetrameric PepTSo2 was achieved through a low-resolution crystal 
structure revealing the overall assembly of the tetramer (Figure 22 D). This homo-tetrameric 
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state forms the basis for further investigations where a higher-resolution X-ray or Cryo-EM 
structure would shed more light on the molecular details of this arrangement. Furthermore, 
biochemical assays are necessary to unravel whether the subunits in the tetramer function in a 
cooperative or independent mode. Results gathered in these two papers together give new 
important insights into substrate recognition, substrate preference and the quaternary state of 
POTs.  
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Figure 22. A) The artificial dimer crystal packing obtained from the high resolution P212121 crystal form. The 
two molecules are coloured differently and the HA-HB helices are coloured in grey to facilitate the visualization 
of the symmetry. The dimer interface is stabilized by a zinc ion coordinated by two asparagines, shown as stick s 
and coloured in red. B) A comparison between alafosfalin position in PepTSo2 and GkPOT. PepTSo2 is shown as a 
grey cartoon and the alafosfaline molecules are annotated and shown as sticks. C) A comparison between AAA 
coordination by PepTSo2 and PepTSt. PepTSo2 is shown as a gray cartoon and the AAA peptides are annotated and 
shown as sticks. D) The low-resolution homo-tetramere structure of PepTSo2 obtained from a P3121. The four 
units are coloured differently and the HA-HB are coloured in grey to facilitate the visualization of the symmetry. 
D) The homo-tetramere structure of PepTSo2 obtained fro a P3121 crystal form at a resolution of 4.6 Å. The four 
units are coloured differently and the HA-HB helices are coloured in grey to facilitate the visualization of the 
symmetry.  
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6 Future Perspectives 
 
Ever since the human peptide transporters PepT1 and PepT2 were identified as drug uptake 
systems, there have been a large number of scientific studies to unravel their molecular 
mechanisms. However, human IMPs are not only challenging to produce but also difficult to 
keep in a stable and functional state leading to extreme difficulties in handling and 
crystallizing them. The field has therefore turned towards the more stable prokaryotic 
homologs (POTs). Due to the high conservation they can be used as interesting model 
systems to study mechanistic details, also relevant for the human proteins. An alternative 
possibility is the “humanization” of prokaryotic POTs through key mutations, generating a 
transporter more similar to the human transporters. The mutants could then be used as a 
platform for understanding of the human transporters.  
The field of POTs has in recent years experienced great progress, several high-resolution 
structures were determined, some of them even bound to substrates. These structures enabled 
us to, for the first time, visualize molecular details of these transporters, identify key residues 
in the binding site, and monitor conformational changes. Nevertheless, in spite of the 
abovementioned novel insights, key questions still remain to be addressed, particularly 
concerning the proton coupling mechanism, structural insights into various conformations, 
the kinetics of the transport event, transport regulation, and the quaternary state.  
During my PhD thesis, several attempts were made aiming at crystallizing PepTSo2 in various 
conformations. Some of the techniques performed include co-crystallization with specific 
binders such as inhibitors and nanobodies. Furthermore, mutations were inserted at specific 
gating residues in order to lockup the gates and stabilize a particular conformation. Other 
approaches such as crystallization in different detergents, in lipid cubic phase, and in lipidic 
bicelles were also attempted. Although some of these methods yielded initial crystallization 
hits, more work is required for further optimizations. 
To tackle the tertiary structure of PepTSo2, an in-house nanoparticle technology was 
developed 116. This novel approach is based on the lysosomal saposin protein, known for 
having a lipid modulator activity 117. They are composed of amphipathic helices enabling the 
assembly of nano-disc structures where hydrophobic molecules can be incorporated. The 
tetrameric PepTSo2 was successful incorporated in the saposin nanodiscs and has proven to be 
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a promising target for Cryo-EM studies. So far, an initial low-resolution tetrameric structure 
was obtained and more particles will be collected to improve the resolution. 
One of the most applied methods here is the X-ray crystallography. This is also one of the 
main challenges in the field of IMPs. It is a very tedious and labour-intensive process based 
on a huge number of crystallization experiments where thousand of conditions and crystals 
are screened before a well diffracting crystal is identified. The pathway from a purified IMP 
to a well diffracting and reproducible crystallization condition is thus very long and 
complicated. Furthermore, the diffraction of IMP crystals is often anisotropic and of poor 
resolution. This imposes huge difficulties for the model building process that has to be 
performed by many iterative cycles. It is therefore of great interest to find new and alternative 
methods that can enable a faster and easier way of solving IMP structures. The lipid cubic 
phase (LCP) crystallization method is an alternative crystallization method where the IMP is 
crystallized in a membrane-mimetic matrix. This technique has gained a lot of attention 
recently due to success in delivering high-resolution structures of various IMPs, including 
human targets. Another alternative method is the use of X-ray free-electron laser (XFEL) an 
innovative new opportunity where structural information is collected from micro-crystals. 
However, the advantage of this method compared to current strategies for data collection 
need to be proven. The most exciting method for IMP structure determination is probably 
Cryo-EM. Here, the crystallization step is bypassed since structural information is collected 
straight from a protein sample without the need of solving any phases. Furthermore, these 
experiments have the potential to monitor several conformations of the protein in a single 
experiment. Several IMP structures have recently been determined using Cryo-EM and it will 
be very interesting to see how generally applicable it is for future routine structure 
determinations of IMPs. 
For many years structural biology of membrane proteins was seen as a very challenging field. 
However, due to the great dedication from researchers all over the world towards developing 
more efficient and robust strategies for IMP production, crystallization and structure 
determination the future of IMP structural biology is bright. In the near future we will likely 
experience a continued rapid increase in solved membrane protein structures including 
human IMPs which will enable us to understand the molecular mechanisms of a larger 
fraction of the biology of the membrane, as well as utilize the structural information to enable 
more efficient development of novel drugs. 
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7 Svensk populärvetenskaplig sammanfattning 
 
En levande cell kan liknas vid ett hus där väggarna är cellmembranet och dörrarna är integrala 
membranproteiner, en sorts proteiner som sitter i cellmembranet och har kontakt med både cellens 
insida och dess omgivande miljö. Cellmembranet skyddar och avgränsar cellinnehållet från 
omgivningen medan integrala membranproteiner ansvarar för bland annat kontroll och reglering av 
molekyltransport över cellmembranet samt kommunikation med omgivningen. Varje molekyl som ska 
in eller ut ur cellen har tilldelats ett specifik integralt membranprotein, en transportör, genom vilken 
den tillåts passera.  
Denna studie behandlar en sorts integrala membranproteiner som tillhör kategorin peptidtransportörer. 
De finns i tunntarmens vägg där de ansvarar för absorption av intaget födoprotein och möjliggör på så 
sätt näringsupptag vid förtäring. Intressant nog är många peptidtransportörer nödvändiga även för 
upptag av olika typer av läkemedel, till exempel antibiotika. Ökade kunskaper om dessa proteiner och 
deras egenskaper som läkemedelstransportörer är därför av stor betydelse för framtagning av 
läkemedel som kan tillföras kroppen via oralt intag. I detta arbete har jag velat studera och förstå hur 
peptidtransportörerna ser ut, deras tredimensionella proteinstruktur. Utan en proteinstruktur kan man 
endast spekulera om hur vissa läkemedel tar sig igenom transportören och varför vissa läkemedel inte 
kan ta sig igenom. Den kunskap som en proteinstruktur tillför läkemedelsutvecklingen kan spara år av 
arbete och möjliggör riktad design av läkemedel som har rätt egenskaper för att kunna passera igenom 
transportören på ett effektivt vis.   
Jag har under min doktorandtid fokuserat på att förstå funktionen och strukturen på 
peptidtransportörer som härstammar från olika organismer. Den vanligaste metoden för 
proteinstrukturbestämning kallas röntgenkristallografi och bygger på att man först genererar kristaller 
från en lösning av framrenat protein och sedan skjuter röntgenstrålar genom dessa. Röntgenstrålarna 
sprids när de passerar kristallen och bildar ett mönster som fångas av en detektor. Detta s.k. 
diffraktionsmönster innehåller information om proteinets atomära struktur. Vägen från idé till ett 
framrenat protein och vidare till en färdig struktur är emellertid lång och tidskrävande, särskilt vad 
gäller integrala membranproteiner Våra strukturella studier på peptid transportörer har tillåtit oss att få 
en inblick i hur dessa proteiner ser ut och hur de fungerar. Detta kan vara första steget mot en mer 
rationell design av läkemedel som tas upp effektivare av kroppen. I framtiden vill man även designa så 
kallade ”pro-drugs”, läkemedel som man kopplar till en aminosyra för att göra dem mer peptidlika. På 
så sätt kan läkemedelsmolekylerna lättare följa med ut i blodcirkulationen. 
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